The effect of iron depletion on chronic hepatitis C virus infection

Massimo Franchini1, Giovanni Targher, Franco Capra

  • 1Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Azienda Ospedaliera di Verona, Ospedale Policlinico, Piazzale Ludovico Scuro, Verona, 37134, Italy, mfranchini@univr.it.

Hepatology International
|August 12, 2009
PubMed

Insights

Iron overload in chronic hepatitis C virus (HCV) infection worsens liver damage. Reducing iron levels through phlebotomy may improve patient outcomes and response to interferon therapy.

Area of Science:

  • Hepatology
  • Virology
  • Iron Metabolism

Background:

  • Chronic hepatitis C virus (HCV) infection is frequently associated with iron overload.
  • Iron excess is implicated in the pathophysiology and progression of liver disease in HCV patients.

Purpose of the Study:

  • To review the mechanisms of iron-induced liver damage in HCV.
  • To evaluate the benefits of iron depletion (phlebotomy) on patient outcomes.
  • To assess the impact of iron reduction on interferon therapy response.

Main Methods:

  • Literature review of studies on iron overload in HCV.
  • Analysis of mechanisms linking iron excess to liver injury.
  • Examination of data on phlebotomy and its effects on biochemical and histological markers.
  • Review of studies investigating iron reduction and interferon treatment efficacy.

Main Results:

  • Iron overload contributes significantly to liver damage in chronic HCV.
  • Phlebotomy can lead to improvements in biochemical and histological outcomes.
  • Reduced iron levels may enhance the effectiveness of interferon antiviral therapy.

Conclusions:

  • Iron overload is a critical factor in HCV liver disease progression.
  • Iron depletion strategies, such as phlebotomy, offer therapeutic benefits.
  • Managing iron levels is important for optimizing treatment response in HCV patients.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...